Clinical Trial Update: Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing ruxolitinib (INCB018424) in participants with primary myelofibrosis and related post-MPN myelofibrosis conditions has completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myeloproliferative Neoplasms
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: MPN (Myeloproliferative Neoplasms) | Phase 2 | Status: COMPLETED | Results posted: 2020-01-28